The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.
Bone mineral density
Denosumab discontinuation
Oteoporosis
Rebound
Zoledronate
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
14
05
2023
accepted:
12
07
2023
medline:
25
9
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
The long-term effects of zoledronate treatment in women with postmenopausal osteoporosis who stop denosumab therapy when they become osteopenic are not known. In a prospective, randomized, controlled clinical trial we previously reported that a single intravenous infusion of zoledronate 5 mg given to such patients 6 months after the last denosumab injection effectively prevents bone loss in the majority of them for up to 3 years. The study was extended for an additional 2 years and included all 19 patients from one Trial Site of the total 27 patients originally randomized in the zoledronate arm. Baseline characteristics of this cohort treated with denosumab for 2.4 ± 0.2 years were not different from those of the whole initial cohort or from the patients who did not participate in this extension. At the end of 5 years 7 patients had become again osteoporotic requiring additional treatment, 9 remained osteopenic while 3 did not complete the study extension. Thus, more than half of the osteoporotic women who became osteopenic with denosumab treatment and stopped it, maintained the BMD gains 5 years after a single zoledronate infusion with no additional treatment. Whether these results are also applicable to patients treated with denosumab for longer periods remains to be established.
Identifiants
pubmed: 37535102
doi: 10.1007/s00223-023-01119-7
pii: 10.1007/s00223-023-01119-7
doi:
Substances chimiques
Zoledronic Acid
6XC1PAD3KF
Denosumab
4EQZ6YO2HI
Bone Density Conservation Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
469-473Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa756
doi: 10.1210/clinem/dgaa756
pubmed: 33103722
Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing Denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34(12):2220–2228
doi: 10.1002/jbmr.3853
pubmed: 31433518
Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478
doi: 10.1016/j.bone.2020.115478
pubmed: 32534221
Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35(7):1207–1215
doi: 10.1002/jbmr.3962
pubmed: 31991007
Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate–results from a randomized double-blind placebo-controlled trial. Bone 50(6):1389–1393
doi: 10.1016/j.bone.2012.03.016
pubmed: 22465268
Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39(1):58–74
doi: 10.1007/s12325-021-01936-y
pubmed: 34762286
Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, de Gregomicronrio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM (2019) Relationship between bone mineral density t-score and Nonvertebral fracture risk over 10 years of Denosumab treatment. J Bone Miner Res 34(6):1033–1040
doi: 10.1002/jbmr.3722
pubmed: 30919997
Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after Denosumab discontinuation: freedom and freedom extension trials additional post hoc analyses. J Bone Miner Res 37(11):2112–2120
doi: 10.1002/jbmr.4705
pubmed: 36088628
Sølling AS, Harsløf T, Langdahl B (2020) Treatment with Zoledronate subsequent to Denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35(10):1858–1870
doi: 10.1002/jbmr.4098
pubmed: 32459005
Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of Denosumab treatment and the efficacy of Zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106(10):e4155–e4162
doi: 10.1210/clinem/dgab321
pubmed: 33978745
Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307–317
doi: 10.1038/s41584-023-00935-3
pubmed: 37024711
Burckhardt P, Faouzi M, Buclin T, Lamy O (2021) The Swiss Denosumab study, fractures after Denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717–1728
doi: 10.1002/jbmr.4335
pubmed: 34009703
Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830
doi: 10.1016/j.bone.2020.115830
pubmed: 33359006